Could a lower dose of regorafenib help fight a rare cancer?

NCT ID NCT02098538

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 26 times

Summary

This study tested the drug regorafenib in 38 people with a rare cancer called adenoid cystic carcinoma that had spread or come back. Regorafenib is already approved for other cancers, but this trial used a lower starting dose to reduce side effects. The goal was to see if the drug could shrink tumors or stop them from growing, and to monitor safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States

Conditions

Explore the condition pages connected to this study.